stand firmli strong foundat win growth strategi
maintain buy rate agil tp
deriv tp ep along earn
multipl estim top line growth
compani perform well consid continu
double-digit growth oper net margin strong order
demand europ higher end mass spectrometri
technolog continu growth end market
uptak agil agil program streamlin compani
continu process improv
agil finish post strong number yet anoth
quarter profit ep continu grow double-digit
market perform well led double-digit growth chemic
busi
end market perspect chemic
revenu grew third consecut quarter double-
digit revenu growth growth broad-bas across
spectrum explor refin chemic
mn except ep
total revenu agil quarter grew
compar adjust ep
quarter beat estim net
incom quarter increas
compar ep
compar achiev growth
y/i
compani name inc tickerastock ratingbuyunchangedindustri viewneutralpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
net incom quarter increas
compar net margin
compar
ep compar
achiev growth y/i
geograph revenu contribut total
revenu quarter europ
contribut total revenu quarter
asia pacif contribut total revenu
quarter stood
revenu grew y/i core basi led double-digit
growth academia government food chemic
busi diagnost clinic end market revenu
grew y/i core basi due strong growth
patholog companion diagnost balanc gain
announc expans sureguid pool crispr
librari function genom offer pool librari
crispr activ interfer crispr a/i
flexibl agil platform bring research
crispr a/i librari incorpor gene target develop
univers california
guidanc expect revenu
rang core growth mid-
point core report ep expect
assum dilut share
agil agil program continu streamlin compani
upgrad system infrastructur drive
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short n/a short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date dec last split factor new per last split date inform agil technolog inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
incom statement month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research depreciation/amortization- interest expens incom net operating- unusu expens incom oper expens total- total oper oper interest incom expens net non-operating- loss sale assets- incom incom minor interest- equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut adjustment- dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli inc| januari
 term short term receiv trade receiv current asset current total term long term asset payable/short term port lt debt/capit current liabil current term leas long term incom liabil prefer stock stock non redeem stock paid-in earn accumul stock equiti liabil sharehold out common stock primari common share annual actual quarterli balanc sheet item agil inc| januari
financi posit octob consist cash cash equival
compar octob
net cash provid oper activ compar provid
compani paid net tax compar net tax
increas cash usag year end octob asset liabil primarili due
pension contribut tax
fiscal year compani retir million treasuri share aggreg cost
month end month end month end month end month end month end month end month end income/start work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid agil technolog inc| januari
agil finish post strong number yet anoth quarter profit
ep grew double-digit genetisur dx postnat assay receiv
clearanc end-market perform well led double-digit growth chemic
busi adjust ep quarter beat
estim
total revenu agil quarter grew compar
primarili grow across core busi
doubl digit growth chemic food academia government
busi across major geographi mainli china europ foreign
exchang posit impact quarter
cog quarter compar
increas y/i gross margin quarter stood compar
increas y/i reflect higher sale volum
unfavor product mix wage increas partial off-set favor
 expens quarter grew y/i compar
primarili due increas program spend new
product busi addit increas
headcount acquisit done past year result increas
total revenu
agil quarter
grew
compar
gross margin
quarter stood
compar
oper incom
quarter grew
y/i
compar
oper
margin quarter
compar
sg quarter flat compar
oper incom quarter grew y/i compar
oper margin quarter
compar total oper margin increas due
initi cost lower acquisit integr cost
net incom quarter increas compar
net margin compar
ep compar
achiev growth y/i
total revenu
quarter
compar
 contribut total revenu quarter increas
y/i compar
europ contribut total revenu quarter
compar increas y/i
asia pacif contribut total revenu quarter stood
increas compar
contribut total
revenu dx
contribut total
revenu type instrument revenu contribut total
revenu consum servic informat contribut total revenu
quarter
revenu major market analyt laboratori contribut total
revenu dx clinic market contribut total revenu
revenu segment lsag contribut total revenu acg contribut
total revenu dgg contribut total revenu
result revenu end-market
agil growth end-market led robust chemical/energi
academic/govern food result offset soft pharma
chemic
environ forens
dx clinic
academia govern
pharma
y/i core basi
pharma part due expect nasd declin
defer revenu recognit strong european lcm busi
academia government driven demand europ us
environment forens led strength china europ
demand gc gc/m icp/m
food led servic consum mass spec region strength
europ asia
chemic broad-bas gain across region product
sub-seg
diagnost clinic end market revenu grew y/i core
basi due strong growth patholog companion diagnost
pharma
part due
defer revenu
recognit strong
european lcm
chemic
broad-
region product
diagnost clinic
grew y/i core
basi due strong
growth patholog
companion
diagnost
total revenu agil grew compar
increas due growth across core busi
growth end-market led chemic busi across major
cog compar increas
y/i increas due higher sale volum unfavor product mix
wage increas
 compar increas
y/i primarili due increas program spend new product
sg flat y/i compar
ebit compar increas
y/i oper margin compar
total oper margin increas due improv gross margin
net incom increas compar
net margin compar
ep compar achiev growth
y/i
net cash provid oper activ compar
provid agil paid net tax
compar net tax increas cash usag year
end octob asset liabil primarili due pension
contribut tax
total revenu
agil grew
compar
increas due
growth across core
busi growth
end-market led
busi across
net incom
increas
compar
net
margin
compar
ep
compar
y/i
life scienc appli market group lsag
life scienc appli market busi provid application-focus
solut includ instrument softwar enabl custom
identifi quantifi analyz physic biolog properti substanc
product well enabl custom clinic life scienc
research area interrog sampl molecular cellular level
revenu lsag quarter increas y/i
compar increas due growth chemic
energi academia govern food end market lsag oper
margin quarter
revenu lsag increas y/i
compar increas due growth chemic
energi academia govern food end market lsag oper
margin quarter
geograph wise revenu increas america europ
unfavor currenc impact increas asia pacif
informat system cell analysi system led doubl digit growth
year ga chromatographi return strong growth strength
rebound chemic energi market
revenu lsag
quarter
y/i compar
increas
america europ
unfavor
currenc impact
increas asia
life scienc appli market group lsag
end market end market perform show shift growth trend
chemic energi market rebound sharpli
depress level deliv strong growth growth
pharmaceut market modest reflect difficult y/i comparison food
environment market demonstr continu growth year life
scienc research diagnost clinic market sale saw improv
year progress
gross margin segment compar
increas due combin moder price increas margin
improv initi reduc logist cost
 expens quarter increas y/i compar
due higher project invest across busi well
higher wage variabl pay
sg expens quarter increas compar
primarili due increas wage increas variabl pay
target program spend increas sale
oper incom lsag increas y/i
compar oper margin
compar increas due higher revenu
lower cost sale increment revenu
agil enter platinum sponsorship agreement labcentr
biotech innov hub base cambridg mass agil equip
labcentr share laboratori workspac varieti technolog
includ high-resolut mass spectrometri system well cell analysi
show shift
growth trend
chemic
energi market
rebound sharpli
depress level
deliv
oper incom
lsag
y/i compar
agil equip
varieti
spectrometri system
well cell analysi
agil cross lab busi span entir lab extens consum
servic portfolio design improv custom outcom
major portfolio vendor neutral mean agil serv suppli
custom regardless instrument purchas choic solut rang
chemistri suppli servic softwar help connect entir
revenu acg segment quarter increas
y/i compar across servic consum
region end market acg oper margin quarter
revenu acg segment increas y/i
compar increas led increas core
servic lab enterpris servic led term percentag growth
remarket instrument busi
geograph wise revenu increas america increas
europ unfavor currenc impact increas asia pacif
unfavor currenc impact
revenu acg
segment quarter
increas
y/i compar
increas
europ
impact increas
asia pacif
end market acg saw posit revenu growth key end market
except forens market revenu growth
percentag perspect led food market pharmaceut
biotechnolog market saw slower growth prior year mostli
due tougher comparison still primari growth driver
volum perspect chemic energi market provid level
strong revenu growth
gross margin segment flat compar
due higher sale volum off-set higher wage
 expens increas compar
increas expens primarili due increas invest
relat acquisit well higher wage variabl pay
sg expens increas compar
due higher order increas sell cost wage variabl pay
addit oper expens due acquisit
oper incom acg segment increas y/i
compar due higher sale volum help off-set
growth number servic workforc higher wage variabl pay
agil cross lab servic support organ cross mark
order singl fiscal year
agil turn servic busi key differenti
offer short period sinc creation acg
servic agil becom strateg partner
custom help achiev improv lab effici busi
revenu growth
key end market
except forens
growth
led food
oper incom acg
segment
y/i compar
servic support
organ cross
mark order
diagnost genom group dgg
diagnost genom busi includ genom nucleic acid contract
manufactur patholog companion diagnost reagent
partnership busi diagnost genom busi compris five
area activ provid solut includ reagent instrument softwar
consum enabl custom clinic life scienc
research area interrog sampl cellular molecular level
revenu dgg segment quarter increas
compar led increas demand patholog
product companion diagnost servic dgg oper margin
quarter
revenu dgg segment increas
compar increas due posit growth
busi region led strong revenu growth companion
diagnost patholog busi nucleic acid busi saw continu
market demand nucleic acid solut busi relat therapeut oligo
program patholog busi saw steadi growth due strong util
agil dako omni platform strength assay
revenu dgg
segment quarter
increas
compar
revenu increas
america
europ increas
asia pacif
geograph wise revenu increas america currenc
impact increas europ unfavor currenc impact
increas asia pacif unfavor currenc impact
end market diagnost clinic research continu strong
grow driven age popul lifestyl
gross margin product servic increas
compar mainli driven higher volum
 expens increas y/i compar
spend increas due acquisit higher wage
sg expens increas compar
due addit oper expens associ acquisit
higher wage variabl pay partial off-set reduc expens due
oper incom compar
increas y/i margin improv driven higher revenu
volum partial off-set ad cost structur acquisit higher
wage variabl pay
signific fda approv receiv quarter
fda approv expand use cancer diagnost merck
keytruda bristol-my squibb opdivo
genetisur dx postnat assay receiv clearanc agil first
compar genom hybrid cgh assay approv fda
increas
america
increas europ
unfavor
currenc impact
increas asia
pacif
impact quarter
oper incom
compar
increas
clearanc
assay approv
fda diagnost use
agil recent action profit growth plan includ
deliv agil agil initi
multi-year program increas effici custom focu
oper margin y/i consecut quarter
portfolio invest go-to-market capabl
acquir cobalt light system ad raman spectroscopi agil
oper margin
y/i
acquir molecular
sampl barcod
patent portfolio
posit target
acquir molecular sampl barcod patent portfolio
posit target enrich solut
continu construct nucleic acid solut facil expans
announc expans
sureguid pool
crispr librari
crispr activ
introduc revolutionari ultivo lc-m tripl quad asm ultivo
smaller footprint previou instrument yet deliv
better perform predecessor
introduc gc/q-tof system avail commerci
combin high-resolut accurate-mass gc/m low-energi
ioniz sourc make possibl scientist employ techniqu
previous practic
announc expans sureguid pool crispr librari
function genom offer pool librari crispr activ
interfer crispr a/i flexibl agil platform bring
research crispr a/i librari incorpor gene target develop
univers california
agil expect full year revenu rang
growth mid-point core report
agil expect oper margin mid-point
adjust keysight bill classifi incom
ep expect rang assum dilut share
count non-gaap tax rate
compani expect net interest expens plu incom
includ keysight bill
agil aim return dividend author repurchas
share subject market condit
agil expect depreci capital-expenditure oper
respect
expect revenu rang
core growth mid-point report
ep expect assum dilut share
agil expect full
year revenu
rang
growth
mid-point core
report
depreci capital-expenditure
oper
expect
revenu rang
core growth
mid-point core
report
agil saw growth overal busi segment agil continu see
oper net margin grow double-digit consecut
quarter net margin oper margin saw double-digit growth
quarter well
lsag tremend year innov front launch sever new
high-impact product ultivo lc-m tripl quad smaller
footprint predecessor genetisur dx postnat assay receiv
clearanc agil first compar genom hybrid assay
approv fda diagnost use
compani experienc strong order demand europ higher end
mass spectrometri technolog order revenu cycl longer
europ type product
end market perspect chemic revenu grew
third consecut quarter double-digit revenu growth growth
broad-bas across spectrum explor refin chemic lc
replac cycl continu small molecul market segment
slow rate nasd revenu also expect compani
agil agil program continu streamlin compani upgrad
system infrastructur drive continu process improv agil
roa roe quarter respect ep
quarter
lsag tremend
year innov
product
smaller
footprint
continu small
segment
revenu also
expect
continu streamlin
compani
upgrad system
infrastructur drive
non- reconcili
non- reconcili
non- reconcili
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
revenu growth compar
ep growth ttm compar
oper growth compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth agil inc| januari
mrqgross mrqcog mrqoper mrqsg mrqr mrqnet margin agil technolog inc| januari
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale agil inc| januari
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item agil technolog inc| januari
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang agil inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form michael paul boon institut holdersholdershar report outvaluepric row associ vanguard group inc fmr jp morgan state mutual automobil insur putnam invest primecap manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market price row mid cap growth vanguard price row spdr etf vanguard institut fund-institut price row valu fidel magellan fund vanguard growth ishar inc| januari
developmentsagil receiv multipl innov award analyt scientist announc analyt scientist recogn compani product among innov year magazin special analyt chemistri name agil ultivo tripl quadrupol lc/m system togeth agil infin ii prime lc agil captiva enhanc matrix removallipid technolog list top innov agil thought leader award present renown drug discoveri research professor jiandong jiang announc professor jiandong jiang receiv agil thought leader award support studi cancer stem cell differenti induc natur product professor jiang director institut materia medica imm chines academi medic scienc cam peke union medic colleg pumc beij china agil sponsor food analysi symposium pragu announc showcas recent technolog advanc symposium recent advanc food analysi rafa held ember pragu agil major sponsor rafa held everi two year premier scientif event address food analysi applic rafa draw food scientist academia industri well govern regul around world agil expand sureguid portfolio crispr-bas product acceler diseas research oct announc first expans sureguid pool crispr librari function genom offer pool librari crispr activ interfer crispr a/i announc made american societi human genet confer ashg held octob orlando florida decemb inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock
outperform
price-to-earnings ratio
higher industri average
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit agil inc| januari
consensu view analyst trend stock
forecast agil
higher
average
forward price-to-earnings
higher
 avgfive-year growth forecast usdgrowth high day day day estim comparisonaindustri avg avgprice/earn yield inc| januari
consensu view analyst trend stock
earn growth estim
revenu growth estim
respect
adjust ep estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last daysn/an/an/an/aup last daysn/an/an/an/adown last daysn/an/an/an/adown last dayscurr growth ratescurr surprisescurr analyst recommend
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock reach level fall level stock price
stock gave total return last month
stock shown consist uptrend price sinc dec given total return
stock reach fresh high
stock show uptrend sinc oct given total return last year
stock shown signific rise price sinc oct reach all-tim high
sept
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
